GHK-Cu

Background

Glycyl‑L‑histidyl‑L‑lysine–copper(II) (GHK‑Cu) is a naturally occurring tripeptide–metal complex first described in 1973, when Pickart identified a factor in human plasma albumin that caused aged human liver tissue to synthesize proteins characteristic of younger tissue.[11][12] Subsequent structural characterization established GHK as a high‑affinity copper‑binding peptide that readily chelates Cu(II) to form GHK‑Cu.[11][14]

Physiological GHK concentrations in human plasma are approximately 200 ng/mL at age 20, declining to about 80 ng/mL by age 60, suggesting an age‑related reduction in endogenous GHK/GHK‑Cu availability.[14] The complex has been detected in plasma, saliva, and urine and is generally regarded as an endogenous modulator of tissue repair and remodeling.[11][14]

Since the 1980s, GHK‑Cu has been investigated as a cosmeceutical and regenerative peptide, particularly for skin aging, wound repair, and hair growth.[11][14][15] It is now widely incorporated into cosmetic formulations (creams, serums, eye products, and hair tonics), often classified as a cosmetic ingredient rather than a drug in the US and EU regulatory frameworks.[15]

Mechanism of action

Copper binding and transport

GHK has a very high affinity for Cu(II), forming a square‑planar GHK‑Cu complex that can function as a low‑molecular‑weight copper transporter, potentially delivering copper to enzymes that require it as a cofactor (e.g., lysyl oxidase, superoxide dismutase).[11][14][15] This copper shuttling is thought to underlie part of its antioxidant and matrix‑remodeling effects.[11][14]

Gene expression modulation

Microarray and systems biology analyses show that GHK/GHK‑Cu can up‑ or down‑regulate hundreds to thousands of human genes involved in tissue remodeling, antioxidant defense, DNA repair, and inflammation.[11][14][15] An in‑silico analysis cited by Pickart et al. reported beneficial modulation of genes related to oxidative stress, wound healing, and nervous system function, supporting a role as a broad pro‑regenerative signal rather than a single‑target ligand.[11][14]

Extracellular matrix and wound repair

Preclinical in vivo and in vitro studies demonstrate that GHK‑Cu:

• Stimulates collagen, elastin, and proteoglycan synthesis in dermal fibroblasts and wound models.[13][15]
• Increases accumulation of dermal connective tissue and glycosaminoglycans in rat wound chambers.[13]
• Modulates matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), shifting the balance toward matrix preservation and remodeling.[4][15]

These actions are consistent with improved wound contraction, re‑epithelialization, and dermal matrix quality.[13][15]

Anti‑inflammatory and antioxidant effects

GHK‑Cu reduces reactive oxygen species (ROS), increases superoxide dismutase (SOD) activity, and down‑regulates pro‑inflammatory cytokines such as TNF‑α and IL‑6 in cell culture and animal models.[6][11][14] In an LPS‑induced acute lung injury (ALI) mouse model, GHK‑Cu suppressed NF‑κB p65 and p38 MAPK signaling, reducing inflammatory cell infiltration and histologic lung damage.[6] Similar anti‑inflammatory and antioxidant properties have been demonstrated in skin and filler‑associated inflammation models.[2][4]

Angiogenesis and neuroregeneration

GHK‑Cu promotes angiogenesis via increased expression of vascular endothelial growth factor (VEGF) and associated pathways, which contributes to improved wound perfusion.[4][7][15] Emerging data suggest neuroprotective and pro‑cognitive effects, including modulation of genes involved in neuronal survival and synaptic plasticity, and improvement of hippocampal‑dependent learning in aged mice.[1][11][12]

Evidence summary

Preclinical studies

1. Connective tissue accumulation in wounds (rat)
   A classic in vivo study using rat subcutaneous Teflon chambers showed that GHK‑Cu significantly increased accumulation of collagen, glycosaminoglycans (notably dermatan sulfate), and overall extracellular matrix compared with saline or a control tripeptide.[13] This provided early evidence that GHK‑Cu directly promotes connective tissue formation in vivo.

2. Acute lung injury (ALI) model (mouse)
   In a lipopolysaccharide‑induced ALI model, GHK‑Cu treatment reduced ROS, increased SOD activity, decreased TNF‑α and IL‑6, and improved histologic lung architecture by limiting inflammatory cell infiltration.[6] Although exact group sizes are not specified in the abstract, this study supports systemic anti‑inflammatory and antioxidant effects beyond skin.

3. Cognitive aging and hippocampal biology (mouse)
   A preprint study in 20–21‑month‑old C57BL/6J mice (sexes combined; group sizes not explicitly stated in the abstract) compared intraperitoneal (IP) versus intranasal (IN) GHK‑Cu at 15 mg/kg.[1] IN administration for 8 weeks improved escape latency on a hippocampal‑dependent spatial navigation task in both sexes, whereas short‑term IP dosing produced only transient effects in males.[1] IN treatment increased synaptophysin expression and reduced astrocytic marker GFAP, with transcriptomic evidence of suppressed oxidative stress and inflammatory pathways.[1] These data suggest route‑dependent neuromodulatory and geroprotective effects but remain preclinical.

4. Dermal and wound healing models
   Multiple in vitro and animal studies, synthesized in recent reviews, show that GHK‑Cu enhances fibroblast proliferation, keratinocyte migration, collagen deposition, and angiogenesis in cutaneous wound models.[4][14][15] In a hyaluronic acid–based hydrogel incorporating Cu‑GHK nanofibers, full‑thickness skin wounds in rodents exhibited accelerated closure, denser collagen remodeling, and increased fibroblast density versus control hydrogels.[7]

5. Soft tissue filler model
   GHK‑Cu loaded onto hydroxyapatite microsphere fillers (GHK‑Cu@CMHA) showed sustained release over 7 days and reduced LPS‑induced inflammatory markers and ROS in vitro, while enhancing SOD activity and collagen deposition in vivo.[2] This supports potential use in mitigating inflammation associated with injectable fillers, though this remains preclinical.

Human clinical and cosmetic data

Human evidence is limited and mostly related to topical cosmetic use rather than rigorously designed therapeutic trials.

• A narrative and scoping review of BPC‑157 and GHK‑Cu identified limited human trials, mostly small studies evaluating skin quality and cosmetic anti‑aging effects; robust randomized controlled trials (RCTs) are lacking.[3]
• A systematic review of dermatologic and delivery studies concluded that GHK‑Cu demonstrates consistent improvement in skin elasticity, firmness, and fine wrinkles in small cosmetic trials and manufacturer‑sponsored studies, but emphasized the absence of large, independently conducted RCTs and the predominance of short‑term, surrogate outcomes.[4]

Sample sizes, randomization methods, and effect sizes are often inadequately reported in the publicly accessible literature, making the clinical evidence low to very low certainty. No completed registered phase 2 or 3 drug trials of GHK‑Cu for systemic indications were identified as of the latest reviews.[3][4][14]

Clinical and research uses

Cosmetic and cosmeceutical uses (off‑label/OTC)

GHK‑Cu is widely used in:

• Topical anti‑aging formulations (creams, serums, eye treatments) aimed at improving fine lines, elasticity, and photoaging‑related changes.[4][14][15]
• Wound care dressings and films incorporating GHK‑Cu or GHK derivatives in hydrogels, biopolymer films, or superabsorbent polymers for enhanced healing in acute and chronic wounds, primarily as investigational products or advanced dressings.[4][7]
• Hair and scalp products, where GHK‑Cu is included to support hair shaft thickness and scalp health; human data remain preliminary.[4][15]

These uses fall largely under cosmetic or medical‑device categories, depending on formulation and jurisdiction, and are not supported by high‑grade therapeutic trial evidence.

Investigational regenerative applications

Preclinical evidence supports exploration of GHK‑Cu for:

• Enhanced soft tissue filler performance and reduction of filler‑induced inflammation.[2]
• Neuroprotective and anti‑cognitive‑aging strategies via intranasal administration.[1][11][12]
• Pulmonary inflammation and ALI/ARDS models.[6]

At present, these remain research applications without approved drug indications.

Dosing context

GHK‑Cu is not approved as a systemic drug; available dosing information derives from preclinical work and topical cosmetic use and should not be interpreted as prescribing guidance.

• Topical cosmetic concentrations: Published cosmetic and cosmeceutical studies typically use GHK‑Cu in the ppm to low‑percent range in creams or serums, sometimes combined with other actives.[4][15] Exact concentrations and regimens vary widely and are often proprietary.
• Wound dressings/hydrogels: Experimental hydrogels and films often incorporate GHK or Cu‑GHK at low millimolar or microgram‑per‑cm² loadings, designed for sustained release over several days.[4][7]
• Systemic animal studies:
  – Cognitive aging mice: 15 mg/kg GHK‑Cu given intraperitoneally for 5 days or intranasally over 8 weeks.[1]
  – ALI mouse model: GHK‑Cu administered systemically (dose and route detailed in full article) reduced inflammatory indices.[6]

There is no standardized therapeutic dosing regimen for humans, and systemic dosing remains investigational.

Safety profile

Topical and cosmetic safety

Copper peptides, including GHK‑Cu, have an extensive history of topical cosmetic use with a generally favorable safety record.[14][15] Reported adverse effects are usually mild and localized:

• Transient skin irritation, erythema, or stinging at application sites.
• Occasional contact dermatitis in sensitive individuals, likely related to excipients rather than the peptide itself in many cases.[4][15]

No significant systemic toxicity has been reported from topical use at cosmetic concentrations.[14][15]

Systemic and preclinical safety

Animal studies have not identified major toxicities at doses used for wound healing or anti‑inflammatory experiments, though formal GLP toxicology programs are not widely published.[6][11][14] Reviews emphasize that systematic human safety evaluation, particularly for chronic systemic administration, is lacking.[3][4][14]

Potential risks and theoretical concerns

• Copper dysregulation: As a copper carrier, excessive systemic exposure could theoretically contribute to copper overload or interact with disorders of copper metabolism (e.g., Wilson disease), although such effects have not been documented clinically for GHK‑Cu at cosmetic exposures.[11][14][15]
• Oncologic considerations: In vitro data show both potential anti‑cancer and pro‑growth signals depending on context.[15] Current reviews do not identify clear carcinogenic risk but recommend caution given GHK‑Cu’s capacity to stimulate proliferation and angiogenesis in wound settings.[4][14][15]

Regulatory status

United States

• Topical/cosmetic use: GHK‑Cu is used as an ingredient in over‑the‑counter cosmetic products. It is not individually approved as a drug by the US Food and Drug Administration (FDA) and is typically regulated under the general framework for cosmetics, provided no disease‑treatment claims are made.[14][15]
• Drug status: As of current literature, GHK‑Cu does not have FDA approval as a prescription drug for any indication. Published reviews and the absence of entries in major drug approval databases indicate that clinical development has not progressed to approved therapeutic status.[3][4][14]

European Union

• Cosmetic ingredient: In the EU, GHK‑Cu functions as a cosmetic ingredient in skin and hair products, subject to the EU Cosmetics Regulation (EC No 1223/2009). There is no evidence of EMA‑approved medicinal product status for GHK‑Cu.[4][14][15]
• Medicinal product status: No centrally authorized medicinal products containing GHK‑Cu are listed in EMA public resources, and academic reviews describe its use in Europe primarily within cosmetics and experimental medical devices or dressings.[4][14]

Overall, GHK‑Cu is currently positioned as a cosmetic/regenerative peptide with extensive preclinical support but limited human clinical trial evidence and no approved systemic drug indications in the US or EU.